Evidence map›Paper›PMID 41528416›Full record

Observational studyNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology2026

Sleep effects in drug-resistant epileptic patients taking perampanel: an observational study.

Fabio Lamanna, Orazio Pardeo, Diana Tilenni, Francesco Luppino, Giuseppe Salafica, Adele Barbaccia, Angelina Laganà, Irene Aricò, Serena Raineri, Giovanni Tripepi and 2 more

Abstract readObservational Study
PubMed Publisher
In one paragraph

Observational study in Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Fabio LamannaNeurophysiopatology and Movement Disorders Clinic, University of Messina, Messina, Italy.
Orazio PardeoNeurophysiopatology and Movement Disorders Clinic, University of Messina, Messina, Italy.
Diana TilenniNeurophysiopatology and Movement Disorders Clinic, University of Messina, Messina, Italy.
Francesco LuppinoNeurophysiopatology and Movement Disorders Clinic, University of Messina, Messina, Italy.
Giuseppe SalaficaNeurophysiopatology and Movement Disorders Clinic, University of Messina, Messina, Italy.
Adele BarbacciaNeurophysiopatology and Movement Disorders Clinic, University of Messina, Messina, Italy.
Angelina LaganàNeurophysiopatology and Movement Disorders Clinic, University of Messina, Messina, Italy.
Irene AricòNeurophysiopatology and Movement Disorders Clinic, University of Messina, Messina, Italy.
Serena RaineriNeurophysiopatology and Movement Disorders Clinic, University of Messina, Messina, Italy.
Giovanni TripepiNational Research Council (CNR), Institute of Clinical Physiology (IFC), Clinical Epidemiology of Renal Diseases and Hypertension, Ospedali Riuniti, Reggio Calabria, Italy.
Rosalia SilvestriNeurophysiopatology and Movement Disorders Clinic, University of Messina, Messina, Italy.
Angelo LabateNeurology Clinic, Department of Biomedicine, Neuroscience, and Advanced Diagnostic (BIND), University of Palermo, Palermo, Italy. angelo.labate@unipa.it.ORCID http://orcid.org/0000-0002-8827-7324

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPerampanel (PER) is a selective non-competitive antagonist of the AMPA receptor. While its efficacy in epilepsy very limited studies have focused on its impact on sleep quality, thus the aim of this study was to assess PER impact on sleep among patients with refractory epilepsy.

methodsPatients were recruited at the Epilepsy Center of the University of Messina, Italy according to the ILAE criteria and received PER as an add-on therapy. Sleep quality (PSQI), daytime sleepiness (ESS), and quality of life (QOLIE-31) were assessed at baseline and follow-up. Efficacy was evaluated based on seizure frequency reduction and classified as worsened, unchanged, < 50% improvement, ≥ 50% improvement, or seizure-free. Patients were also stratified by use of perampanel as first or late add-on therapy. Tolerability was assessed through reported adverse events.

resultsThirty-one patients were followed for six months; one was excluded due to seizure worsening. PER was first add-on in 11 patients, late add-on in 20. Sleep quality and daytime sleepiness showed slight improvement. QOLIE-31 scores showed a mild, non-significant improvement in quality of life, with a significant reduction in seizure worry in late add-on patients. In the first group, 100% were responders (≥ 50% seizure reduction), 27.2% seizure-free. In the late add-on group, 65% were responders, 30% seizure-free (p = 0.043). PER was well tolerated with no severe adverse events. SIGNIFICANCE: PER appears to preserve sleep quality and mildly improve quality of life. Furthermore, PER shows greater efficacy when used as a first add-on therapy in drug-resistant epilepsy.

Indexed as

AnticonvulsantsDrug Resistant EpilepsyPyridonesSleepSleep QualityAdolescentAdultFemaleHumansMaleMiddle AgedNitrilesQuality of LifeTreatment OutcomeYoung AdultAnticonvulsantsNitrilesperampanelPyridonesDrug-resistantFirst add-onPerampanelQuality of lifeSleep qualitySomnolence

Identifiers

PMID41528416

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.